Autopsy report · NCT02746419

The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain

“The company who was sponsoring devices and funding pulled out before we enrolled any subjects.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

University of Chicago

Sponsor type

University, hospital or other

Conditions

Autosomal Dominant Polycystic Kidney Disease

Interventions

Vessix

Participants

0

Trials that died the same way

• Study to Optimize the IOL Constant of a New Multifocal Intraocular Lens
  “Sponsor decided to modify the prototype device used in study” (60% match in meaning)
• Endurant Evo US Clinical Trial
  “This study terminated enrollment due to device failures prior to enrollment completion.” (59% match in meaning)
• Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE
  “Study device no longer available” (59% match in meaning)
• Pasireotide in Hyperinsulinemic Hypoglycemia
  “Funding was withdrawn by Sponsor prior to start of study” (59% match in meaning)
• Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease
  “Device superceded by next generation device. Enrollment stopped, long term follow up was completed in August of 2004.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.